Trending Topic

3 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

We are delighted to present the latest edition of touchREVIEWS in Oncology & Haematology. This issue underscores the evolving landscape of cancer therapeutics, showcasing advances across a wide range of malignancies, from haematologic diseases to solid tumours, through novel mechanisms, emerging biomarkers and personalized treatment strategies. We begin with an editorial by Isabela Wen-Chi Chang […]

Diagnostics and Screening

An Introduction to Diagnostics and Screening

Early detection of tumours is essential to increase the likelihood of complete remission. Screening strategies are not without risk; for example, mammography and prostate-specific antigen screening can lead to the detection of indolent lesions and subsequent overtreatment. Precision medicine has improved screening and diagnostic approaches; tumour-typing of breast tumours for oestrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 has informed treatment options. Many non-invasive diagnostic tools can be used directly at the point of care. It is hoped that advances in the genomic classification may lead to the identification of high-risk individuals in other types of cancer.

Browse our selection of video highlights and short articles from the conference hub, which provide insights into the latest updates from major conferences, and a collection of peer-reviewed articles from the journal portfolio. These are complemented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.

Our supporting partners do not constitute an endorsement of the content on this page.

Mark CompleteCompleted
BookmarkBookmarked

What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career clinicians ready to think beyond the bedside and explore the business of medicine.

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.

Mark CompleteCompleted
BookmarkBookmarked

This year, we are celebrating our inaugural touchONCOLOGY Future Leaders to recognize the outstanding talent that has entered our field in recent years. These individuals are set to innovate and transform oncology and haematology in the years to come.

Mark CompleteCompleted
BookmarkBookmarked

In line with the continuously expanding molecular landscape of cancer, the ESMO Precision Medicine Working Group (PMWG) has revised its recommendations for tumour next-generation sequencing (NGS).

15 mins
Sponsored Content

A review of next-generation sequencing methods for identifying actionable gene fusions and improving outcomes in cancer patients.

53 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchEXPERT OPINIONS
Dr Ana Kiess, Dr Stephen Graves, Dr Jason Starr, Prof. Jorge Garcia, Dr Erik Mittra

Following a scientific primer, the role of radiopharmaceuticals in the management of neuroendocrine tumours and prostate cancer, alongside approaches to support clinical implementation, are explored by leading experts.

37 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchPANEL DISCUSSION
Dr Rachael Grace, Dr Hanny Al-Samkari, Dr Ami J Shah

Three experts discuss the burden and clinical presentation of pyruvate kinase deficiency, as well as current and emerging therapeutic strategies.

37 mins
touchMDT
Mark CompleteCompleted
BookmarkBookmarked
Prof. Régis Peffault de Latour, Dr Will Evans, Ms Jess Ratcliffe

Watch a leading haematologist, a primary care physician and a patient with paroxysmal nocturnal haemoglobinuria (PNH) share their perspectives on the clinical challenges associated with PNH.

Mark CompleteCompleted
BookmarkBookmarked

Cancers of the oesophagus and oesophagogastric junction (OGJ), termed upper gastrointestinal (UGI) cancers, are lethal and constitute a significant public health problem. In 2020, 604,000 cases and 544,000 UGI cancer-related deaths were estimated worldwide.1 UGI cancers are the seventh most frequently diagnosed cancer ...

49 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked

Watch leading specialists within an MDT discuss the importance of biomarker testing and targeted therapies for personalizing management of thyroid cancer

Mark CompleteCompleted
BookmarkBookmarked
Glenn D Braunstein, Joshua J Ofman

Somatic DNA mutational analysis has transformed how we characterize existing cancer and select treatments. For example, circulating tumour cell-free DNA (cfDNA) can be used to select targeted therapies, monitor treatment response and detect disease recurrence.1 However, early attempts with targeted ...

Mark CompleteCompleted
BookmarkBookmarked

Molecular diagnosis and screening of cancer can be approached either in a broad, high-volume manner, or through using targeted, informed searches for specific genes. Technique selection will be critical in balancing patient benefit against healthcare resource cost, and physicians will ...

Mark CompleteCompleted
BookmarkBookmarked

Over the last decade, genomics has become an increasingly important part of cancer care. In some tumor types, such as lung cancer and melanoma, genetic profiling for actionable mutations has become standard clinical practice.1,2 The development of novel targeted molecular ...

Mark CompleteCompleted
BookmarkBookmarked

It has been clearly established that non-small cell lung cancers (NSCLCs) associated with known molecular drivers (e.g., rearrangement of the ALK gene, or mutations activating the epidermal growth factor receptor [EGFR] gene) respond favorably to targeted, first-line therapies compared ...

Mark CompleteCompleted
BookmarkBookmarked

Q. What are the limitations of current methods of detecting biochemical recurrence of prostate cancer? The recommended imaging techniques for the diagnosis of metastases in prostate cancer are 99m-Tc bone scintigraphy for bone metastases and computed tomography (CT) or magnetic ...

Load More...
Close Popup